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Background: Assessing the extent of lung involvement is important for the triage
and care of COVID-19 pneumonia. We sought to determine the utility of point-of-
care ultrasound (POCUS) for characterizing lung involvement and, thereby, clinical risk
determination in COVID-19 pneumonia.
Methods: This multicenter, prospective, observational study included patients with
COVID-19 who received 12-zone lung ultrasound and chest computed tomography
(CT) scanning in the emergency department (ED). We defined lung disease severity
using the lung ultrasound score (LUS) and chest CT severity score (CTSS).We assessed
the association between the LUS andpoor outcome (ICUadmission or 30-day all-cause
mortality). We also assessed the association between the LUS and hospital length of
stay. We examined the ability of the LUS to differentiate between disease severity
groups. Lastly, we estimated the correlation between the LUS and CTSS and the inter-
rater agreement for the LUS. We handled missing data by multiple imputation with
chained equations and predictivemeanmatching.
Results:We included 114 patients treated betweenMarch 19, 2020, andMay 4, 2020.
An LUS ≥12 was associated with a poor outcome within 30 days (hazard ratio [HR],
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5.59; 95% confidence interval [CI], 1.26–24.80; P = 0.02). Admission duration was
shorter in patients with an LUS<12 (adjusted HR, 2.24; 95%CI, 1.47–3.40; P< 0.001).
Mean LUS differed between disease severity groups: no admission, 6.3 (standard devi-
ation [SD], 4.4); hospital/ward, 13.1 (SD, 6.4); and ICU, 18.0 (SD, 5.0). The LUS was
able to discriminate between ED discharge and hospital admission excellently, with an
area under the curve of 0.83 (95% CI, 0.75–0.91). Interrater agreement for the LUS
was strong: κ = 0.88 (95% CI, 0.77–0.95). Correlation between the LUS and CTSS was
strong: κ= 0.60 (95%CI, 0.48–0.71).
Conclusions: We showed that baseline lung ultrasound - is associated with poor
outcomes, admission duration, and disease severity. The LUS also correlates well
with CTSS. Point-of-care lung ultrasound may aid the risk stratification and triage of
patients with COVID-19 at the ED.
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The main cause of morbidity and mortality in COVID-19 is viral
pneumonia, which can progress to acute respiratory distress syn-
drome. Proper evaluation of pulmonary involvement is critical for
appropriate triage, risk stratification, and efficient allocation of med-
ical resources. This is especially important since new, more conta-
gious genetic variants are emerging on multiple continents—some
with the ability to generate more reinfections—which could put addi-
tional stress on already overwhelmed acute care pathways.1 Mount-
ing evidence suggests that imaging studies such as computed tomog-
raphy (CT) are helpful in the diagnosis of COVID-19 pneumonia.
Findings on CT may precede clinical symptoms, and the degree of
pulmonary involvement can help predict patient outcome.2–8 How-
ever, CT is expensive and cumbersome. CT scans can be difficult to
perform on unstable patients, operation of CT equipment requires
extra personnel, and unavailability and high costs can be an issue,
even in high-income countries. In addition, the risk of COVID-19
transmission necessitates stringent desinfection protocols, and clean-
ing of the radiology suite may lead to increased delays between
uses.
Point-of-care ultrasound (POCUS) of the lung might circumvent
these issues. Lung ultrasound has diagnostic accuracy comparable
to CT—and superior to chest radiography—in multiple aetiologies
of respiratory failure, from pneumonia to acute respiratory distress
syndrome.9–15 Recent studies show that lung ultrasound also has
better diagnostic accuracy than chest radiography in diagnosing
COVID-19 pneumonia.18,19 Chest radiography is a poor diagnostic
test in COVID-19 as it may miss up to 40% of confirmed cases.20
Meanwhile, diagnostic accuracy of lung ultrasound approaches that of
CT for COVID-19 pneumonia.21,22 Lung ultrasound can safely exclude
clinically relevant COVID-19 pneumonia and may aid COVID-19
diagnosis in high-prevalence situations.23 The advantages of lung
ultrasound over CT include being fast to operate, simple to clean,
low investment and operating costs, portable, and easily repeatable.
With proper personal protective equipment, lung ultrasound can be
safely performed at the bedside within 10 minutes. Because of its
usefulness in diagnosis and follow-up, lung ultrasound has become
common practice, and even standard practice, in acute and critical
care.16,17
1.2 Goals of this investigation
The literature comparing the degree of pulmonary involvement
between lung ultrasound and CT, along with literature detailing a lung
ultrasound’s ability to stratify patients and predict outcomes, is limited
to only single-center and/or retrospective studies.16,17,24,25 In a recent
meta-analysis, the World Health Organization (WHO) recommended
that the value of lung ultrasound regarding both clinical outcomes and
duration of hospital stay should be investigated further because of
inconclusive evidence.26
1.3 Importance
To address this knowledge gap, we prospectively assessed the value
of lung ultrasound during initial emergency department (ED) presen-
tation in COVID-19 risk stratification and prognostication. In addi-
tion, we also evaluated the correlation between lung ultrasound
and CT results in quantifying lung involvement in patients with
COVID-19.
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2 METHODS
2.1 Study design
We performed a multicenter prospective, observational study. The
studywas registeredwithTheNetherlandsTrial Register andapproved
by the local medical ethical committees.
2.2 Setting
We conducted the study in the following 3 large university hospitals in
TheNetherlands: the RadboudUniversityMedical Center inNijmegen,
the Vrije UniversiteitMedical Center in Amsterdam, and the Academic
Medical Center in Amsterdam. They have 1065, 733, and 1002 beds,
respectively. Each hospital has≈30,000 ED visits per year.
2.3 Participants
Patients were recruited between March 19, 2020, and May 4, 2020.
Inclusion criteria were presentation at the ED for acute internal
medicine, presence of a certified sonographer, confirmed COVID-19,
and lung ultrasound and chest CT performed within 24 hours of pre-
sentation. Exclusion criteriawere either no verbal consent and/or unin-
terpretable CT or lung ultrasound (Figure 1).
Per hospital procedure, all patients received a standard medical
work-up (history, physical examination, common observations, and
routine laboratory tests) and a SARS-CoV-2 polymerase chain reaction
(PCR) test. Clinical criteria for ward admission were oxygen satura-
tion <94% (need for conventional supplemental oxygen) and/or respi-
ratory rate >20/minute. ICU admission criteria were either deteriora-
tion despite conventional respiratory support or need for mechanical
ventilation.
2.4 Lung ultrasound
Lung ultrasound was performed or supervised by acute internal
medicine physicians who are both certified in POCUS and had an
Entrustable Professional Activity level of at least 4. The Entrustable
Professional Activity concept has competency-based education tar-
gets to guarantee that all learners have a sufficient level of proficiency
when they reach the required Entrustable Professional Activity level.
Increasing levels of entrustment range from level 1 (not trusted to
perform POCUS even under direct supervision) to level 4 (entrusted
to use POCUS independently) and level 5 (engagement in POCUS
education and research).27 We predominantly used handheld systems,
with settings amenable to the detection of B-line artefacts.28 The
scanning physician was blinded for the PCR and CT results, but not for
the clinical picture.
The lung ultrasound protocol consisted of a structured assessment
of 6 zones of each hemithorax (Figure 2). Each zonewas scored accord-
The Bottom Line
While correlated with the presence of pneumonia, the asso-
ciation of lung ultrasonography with the clinical outcomes
of COVID-19 has not been studied. In this study of 114
patients with COVID-19 from 3 large university hospitals
in The Netherlands, the extent of lung ultrasonography
(quantified by the Lung Ultrasound Scale) was associated
with important clinical outcomes, including ICU admission
and 30-day mortality. Lung ultrasonography may provide an
important tool for assessing the prognosis of patients with
COVID-19.
ing to the same lung ultrasound score (LUS) classification system used
in intensive care, acute respiratory distress syndrome, and recent
COVID-19 literature.15,16,21,24,29,30 This system scores zones from 0
(well aerated) to 3 (consolidated) (Figure S1). The total LUS sums the
scores from all 12 zones, creating a final score range from 0 (all regions
are well aerated) to 36 (all regions are consolidated).
2.5 Computed tomography
Local radiologists assessed the chest CTs using the COVID-19 Report-
ing and Data System (CO-RADS).2,31–33 The CO-RADS uses a scale
from 1 (very low) to 5 (very high) to indicate the likelihood of COVID-
19 pneumonia. To quantify pulmonary involvement, every CT is graded
according to theCT severity score (CTSS), whenCOVID-19 pneumonia
is suspected (ie, CO-RADS 3 and higher).34 The CTSS is a visual assess-
ment of the percentage of disease involvement in each lobe (Table S1).
The total CTSS is the sum of the individual lobar scores and can range
from 0 (no involvement) to 25 (maximum involvement). The radiolo-
gists were blinded for lung ultrasound and PCR results, but not for clin-
ical information.
2.6 COVID-19 diagnosis
The diagnosis of COVID-19 was established by a positive PCR test
result (from a nasopharyngeal, oropharyngeal, sputum, or broncho-
alveolar lavage sample) or by a clinician impression after alternative
diagnoseswasexcluded. In patientswithhigh clinical suspicionbut neg-
ative PCR, a multidisciplinary team of hospital clinicians determined
the presence of COVID-19 on the basis of clinical, laboratory, microbi-
ological, and/or CT data and only after excluding alternative diagnoses.
Use of clinician impression as a reference is in line with WHO recom-
mendations because of the suboptimal sensitivity of the PCR test.26
The multidisciplinary team is composed of specialists in infectious dis-
ease, respiratory disease, and microbiology and discusses all admitted
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F IGURE 1 Study population flowchart. CT, computed tomography; ED, emergency department; PCR, polymerase chain reaction
(suspected) COVID-19 cases in a daily plenary meeting. The team did
not use lung ultrasound in the determination of COVID-19 presence.
2.7 Outcomes
The primary outcome was poor COVID-19 outcome, defined as the
composite endpoint of 30-day all-cause mortality or ICU admission.
Secondary outcomes includedhospital lengthof stay (days) anddisease
severity groups (ED discharge, hospital ward admission, ICU admis-
sion).
2.8 Statistical analysis
We used Kaplan-Meier curves and Cox proportional hazards regres-
sion to assess the relationship between the LUS and time to poor
outcome (a composite endpoint of 30-day all-cause mortality or ICU
admission) andadmissionduration.Wedichotomized theLUSusing the
median. We tested the proportional hazards assumption by checking
that the Kaplan-Meier curves do not cross and the logminus log curves
run parallel. We assessed linearity for continuous variables by divid-
ing them in tertiles and checking whether β coefficients systematically
increase or decrease with increasing categories.
We reported hazard ratios (HRs; adjusted for any confounders
if applicable) as effect size for the dichotomized LUS used in the
Kaplan-Meier curves as well as for each per-point increase in the LUS
separately. We considered the following variables as potential con-
founders for a relation between the LUS and outcome: duration of
symptoms, age, sex, and comorbidities (chronic obstructive pulmonary
disease, cardiovascular disease, hypertension, and diabetes mellitus).2
We examined confounders separately to keep within the rule of 5–10
events per variable. We used a 10% change in the LUS β coefficient
as confounder threshold.35 We estimated a multivariate model, when
allowed by the events-per-variable rule, in which we adjusted for all
confounders identified.
We compared differences between the following 3 disease sever-
ity grades: (1) mild, no admission/ED discharge; (2) moderate, hospi-
tal/ward admission; and (3) severe, ICU admission. We also compared
means and proportions between these groups by 1-way analysis of
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F IGURE 2 Lung ultrasound protocol and zones of assessment. A 12-zone scanning approachwas used in which the lungs were scanned in a
lawn-mower fashion. This figure shows the 6 scan zones on the right hemithorax. (A) Anterior: Z1 anterior upper zone, Z2 anterior lower zone; (B)
lateral: Z3 lateral axilla zone, Z4 lateral lower zone; (C) posterior: Z5 posterior upper zone, Z6 posterior lower zone. Red line illustrates the “lawn
mower” scanning technique. Each rib space is evaluated tominimize the risk of missing abnormalities. AAL, anterior axillary line; PAL, posterior
axillary line
variance (ANOVA), chi-square test, Fisher exact test, or Kruskal-Wallis
test as appropriate. We used the Tukey honestly significant difference
(HSD) post hoc test to compare pairs of severity grades.
We determined the ability of the LUS to discriminate between dis-
ease severity by comparing receiver operating characteristic (ROC)
curves. We determined the optimal cutoff with the Youden index. We
also reported sensitivity, specificity, positive likelihood ratio, negative
likelihood ratio, and diagnostic odds ratio.36–38 A diagnostic odds ratio
of>10 is considered good.39
We also used a “gray zone” approach.40 This method allows the
binary constraint of a “black or white” decision to be avoided, which
is often inappropriate for clinical or screening practice. Instead, our
approach constructs a 3-zone division for quantitative tests and
purposefully includes a gray zone of inconclusive test results. In this
case, we used a negative likelihood ratio of 0.1 and 0.2 and a posi-
tive likelihood ratio of 10 and 5 for the cutoffs of the gray zone. At
these likelihood ratios, the approximate posttest change in probability
is∼45% (large change) or∼30% (moderate change).41
We employed multiple imputation by chained equations with pre-
dictive mean matching to account for any missing data, assuming a
missing-at-randompattern.Wepooled effect estimates from the impu-
tation data sets usingRubin’s rules.Wegeneratedm=10 imputeddata
sets, because of ≈5%–10% missing data.42 We used all patient char-
acteristics, laboratory values, and radiological information mentioned
in Table 1 and Table S2 with ≤30% missing data for imputation. We
compareddescriptives (eg,means and standarddeviations [SDs]) of the
imputationmodelwith theoriginal data tomake sure all imputedvalues
were plausible.We conducted a sensitivity analysis by also performing
a complete case analysis.35
We quantified the correlation between the LUS and CTSS with the
Pearson correlation coefficient.We assessed interobserver agreement
for the LUSbymeans of the intraclass correlation coefficient (ICC)with
a 2-way randomeffectsmodel. A total of 3 sonographerswith different
levels of experience (Entrustable Professional Activity levels 3, 4, and
5) measured the LUS in a random sample of 20 patients. We used a 2-
sided significance level of 5% for all analyses. We performed all analy-
ses as well as themultiple imputation in SPSS version 26.0.
3 RESULTS
A total of 114 patients were included in the study, and data were
collected between March 19, 2020, and May 4, 2020 (Figure 1). After
initial intake at the ED, 24 patients were discharged home, 79 were
admitted to the ward, and 12 required ICU admission (see Table 1 for
patient demographics and clinical characteristics according to disease
severity group.) A median of 12 lung ultrasound zones were recorded
for each patient. Of the patients, 7 (6.1%) had missing zones, but all
patients included had at least 6 zones scanned. CTSS dataweremissing
for 5 patients (4.4%).
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TABLE 1 Clinical characteristics of patients with COVID-19 undergoing lung ultrasonography




Age, median (IQR) 63 (51,5-74) 57.5 (37-72) 67 (53-75) 61.5 (50,75-67) 0.07 0
Male, n (%) 67 (57.9) 16 (66.7) 41 (52.6) 9 (75) 0.24 0
30-daymortality, n (%) 7 (6.1) 0 (0) 5 (6.4) 2 (16.7) 0.14 0
90-daymortality, n (%) 11 (9.6) 0 (0) 7 (9) 4 (33.3) 0.008 0
Symptom days, median (IQR) 7 (4-10) 7 (5-10) 7 (3-10) 6.5 (5.25-8.5) 0.81 0
Length of stay, median (IQR) 4 (1-8) 0 (0-0) 5 (2-7) 33 (14.25-65.75) <0.001 0
Symptoms, n (%)
Fever 83 (71.9) 21 (87.5) 52 (66.7) 9 (75) 0.14 0
Cough 92 (79.8) 21 (87.5) 61 (78.2) 9 (75) 0.58 0
Dyspnea 75 (65.8) 13 (54.2) 52 (66.7) 10 (83.3) 0.23 0
Abdominal symptoms 45 (39.5) 10 (41.7) 30 (38.5) 5 (41.7) 0.96 0
Comorbidities, n (%)
Cardiovascular disease 22 (19.3) 6 (25) 15 (19.2) 1 (8.3) 0.53 0
Chronic obstructive pulmonary
disease
14 (12.3) 3 (12.5) 10 (12.8) 1 (8.3) 1.00 0
Hypertension 36 (31.6) 7 (29.2) 24 (30.8) 5 (41.7) 0.70 0
Diabetes mellitus 25 (21.9) 7 (29.2) 15 (19.2) 3 (25) 0.53 0
Obesity 35 (30.7) 7 (29.2) 23 (29.5) 5 (41.7) 0.94 0
Malignancy 13 (11.4) 4 (16.7) 7 (9) 2 (16.7) 0.33 0
Vital signs
MEWS, median (IQR) 2 (1-4) 2 (0-2.75) 2.5 (1-3.25) 5.5 (4-6.75) <0.001 0
Systolic blood pressure, mean
(SD)
133 (19) 136 (22) 132 (18) 132 (22) 0.74 0.88
Heart rate, mean (SD) 88 (16) 91 (15) 86 (14) 98 (25) 0.042 0
Respiratory rate, mean (SD) 21 (7) 18 (5) 21 (6) 30 (10) <0.001 3.5
Temperature, mean (SD) 37.7 (1.1) 37.6 (0.7) 37.8 (1.2) 37.5 (1.4) 0.64 0.88
Oxygen saturation, median (IQR) 96 (94-98) 97.5 (96-99) 95.5 (94-97) 92.5 (88.5-96) 0.002 0
Liters of oxygen, median (IQR) 0 (0-3) 0 (0-0) 0 (0-3) 4.5 (0.75-5) <0.001 17.51
Laboratory results
Hemoglobin, mmol/L, mean (SD) 8.1 (1.1) 8.3 (1.3) 8.1 (1.0) 8.5 (1.6) 0.44 0.88
Neutrophils,×109/L, mean (SD) 4.7 (2.7) 3.4 (1.9) 5.0 (2.7) 6.1 (3.4) 0.010 7.02
Lymphocytes,×109/L, mean (SD) 0.97 (0.58) 0.98 (0.59) 0.95 (0.49) 1.1 (0.99) 0.80 7.02
Lactate dehydrogenase, U/L,
mean (SD)
313 (104) 232 (60) 316 (90) 460 (106) <0.001 9.65
CRP, mg/L, median (IQR) 60 (29-118) 26.4 (8.25-53.5) 60 (32-126) 102.5 (65.025-160.5) <0.001 0.88
Creatinine, μmol/L, median (IQR) 80 (60-100) 77 (66.75-102.5) 81 (58-100) 80.5 (64-126) 0.78 2.63
D-dimer, mg/L, median (IQR) 1.02 (0.745-1.82) 0.56 (0.4625-0.8575) 1.09 (1.01-4.6) 1.01 (0.8075-1.47) 0.03 81.58
Hs troponin T, ng/L, median (IQR) 0.015 (0.007-0.027) 0.015 (0.004-0.0225) 0.016 (0.0065-0.2550) 0.045 (0.01050-4.11200) 0.24 58.77
Imaging scores
LUS, mean (SD) 12.2 (6.8) 6.3 (4.4) 13.1 (6.4) 18.0 (5.0) <0.001 6.14
CT severity score, mean (SD) 9.3 (5.0) 4.8 (2.9) 9.9 (4.8) 13.3 (3.8) <0.001 4.39
CRP, C-reactive protein; CT, computed tomography; Hs, high-sensitivity IQR, interquartile range; LUS, lung ultrasound score; MEWS, modified early warning score; SD,
standard deviation.
3.1 Associations between the LUS and patient
outcomes
There were 17 poor outcome events (14.9%) within 30 days. Time to
pooroutcomewas shorter in thegroupwithanLUS≥12comparedwith
the group with an LUS<12. None of the potential confounders altered
the association between the LUS and poor outcome. We found an HR
of 5.59 (95% confidence interval [CI], 1.26–24.80; P = 0.023) in the
imputed data set, with a comparable result in the complete case analy-
sis (Table 2, Figure 3).
Hospital length of stay was longer among patients with an LUS
≥12 (Table 3, Figure 4). We found a crude HR of 1.98 (95% CI, 1.34–
2.93; P = 0.001). Correcting for confounders led to an increase in
the adjusted HR of 2.24 (95% CI, 1.47–3.40; P < 0.001). Analyses
on the imputed data set and the complete analysis yielded similar
results.
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TABLE 2 Associations between lung ultrasound and poor
outcomes in patients with COVID-19
Model HR (95%CI) P value
Lung ultrasound score,
dichotomized at median: 12a
◦Complete case 5.49 (1.24–24.34) 0.03
◦Imputed 5.59 (1.26–24.80) 0.02
Lung ultrasound score, continuousb
◦Complete case 1.11 (1.03–1.21) 0.01
◦Imputed 1.12 (1.04–1.21) 0.004
We report crude (unadjusted) HRs as no confounders were identified. Poor
outcome is defined as the composite endpoint of 30-day all-causemortality
or ICU admission. CI, confidence interval; HR, hazard ratio.
aLung ultrasound score<12 is the reference category.
bHR for poor outcome per point increase in Lung ultrasound score.
3.2 Differences between disease severity groups
There was a statistically significant difference in mean LUS between
the disease severity grades (mild, no admission;moderate, ward admis-
sion; and severe, ICU admission) as determined by 1-way ANOVA
(P < 0.001) (see end of Table 1). The mean LUS data were 6.3 (SD, 4.4),
13.1 (SD, 6.4), and18.0 (SD, 5.0), respectively. TukeyHSDpost hoc tests
for pairwise comparisons revealed significant differences in mean LUS
for all pairs of groups.
3.3 Discriminative ability
The AUC of the ROC curve that depicts the ability of the LUS to
discriminate between hospital admission (ward and ICU combined)
TABLE 3 Associations between lung ultrasound and COVID-19
time to hospital discharge
Model HR (95%CI) P value
Lung ultrasound score,
dichotomized at median: 12a
◦Complete case (crude) 2.02 (1.35–3.00) 0.001
◦Complete case (adjusted) 2.46 (1.58–3.85) <0.001
◦Imputed (crude) 1.98 (1.34–2.93) 0.001
◦Imputed (adjusted) 2.24 (1.47–3.40) <0.001
Lung ultrasound score, continuous
◦Complete case (crude) 1.06 (1.04–1.09) <0.001
◦Complete case (adjusted) 1.07 (1.04–1.11) <0.001
◦Imputed (crude) 1.05 (1.02–1.09) <0.001
◦Imputed (adjusted) 1.06 (1.03–1.10) <0.001
We report crude and adjusted HR. Only duration of symptoms was a signif-
icant confounder. CI, confidence interval; HR, hazard ratio.
aLung ultrasound score≥12 is the reference category.
and no admission was 0.83 (95% CI, 0.75–0.91), which was almost
identical to the CTSS (Figure 5, Figure S1). The optimal cutoff was 12,
with a sensitivity of 70.2%, a specificity of 91.3%, and a diagnostic odds
ratio of 24.8.
Gray zone analysis with a high LR cutoff (ie, negative likelihood ratio
of 0.1 and positive likelihood ratio of 10) showed that patients with an
LUS ≤1 (ie, LUS showing almost no signs of pulmonary involvement)
could be discharged from the ED. We found that patients with an LUS
≥15 almost certainly required admission (Figure 6A). The gray zone
(inconclusive test zone) contained 55.3% of patients. If we reduce the
cutoff to a negative likelihood ratio of 0.2 and a positive likelihood ratio
F IGURE 3 Kaplan-Meier curve for the association between the lung ultrasound score (LUS) and poor COVID-19 outcomes. Kaplan-Meier
curves are based on complete case analysis. Poor outcomewas defined as ICU admission or death at 30 days. The LUSwas dichotomized at the
median of 12
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F IGURE 4 Kaplan-Meier curve for association between the lung ultrasound score (LUS) and time to discharge. Kaplan-Meier curves are based
on complete case analysis. The LUSwas dichotomized at themedian of 12
F IGURE 5 Receiver operating characteristic curves for associations between the LUS, CTSS, and in-hospital admission. AUC, area under the
curve; CTSS, CT severity score; LUS, lung ultrasound score
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F IGURE 6 (A) Gray zone analysis: LUS versus hospital admission— likelihood ratio cutoff= 10. (B) Gray zone analysis: LUS versus hospital
admission— likelihood ratio cutoff= 5. LR+, positive likelihood ratio; LR-, negative likelihood ratio; LUS, lung ultrasound score
of 5, the number of patients within the gray zone decreases to 30.7%
(Figure 6B). Patients with an LUS≥11 had a posttest increase in admis-
sion probability of 30%. A total of 5 patientswere admitted for reasons
not related to the COVID-19 diagnosis, including only 1 patient with-
out any abnormalities on the LUS and 4 patientswithout anyCT abnor-
malities. In fact, all patients with an LUS<3 did not require any supple-
mental oxygen.
3.4 Correlation between the LUS and CTSS
We found a strong positive association between the LUS and CTSS,
with a Pearson correlation coefficient of 0.60 (95%CI, 0.48–0.71). The
interrater agreement for the LUS was excellent, with an ICC of 0.88
(95%CI, 0.77–0.95).
3.5 Limitations/bias
Our study has several limitations. First, although we included consec-
utive patients when a certified sonographer was present, we could not
include every patient who tested positive for COVID-19. However, we
tried to enroll every eligible patient when a certified sonographer was
present, therefore minimizing any possible selection bias. We there-
fore feel that these omissions have not influenced our results. We
look forward to seeing these results corroborated in different settings.
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Second, the wide CIs of the HRs in the poor outcome analysis are
an indication of the imprecision of the estimate. This is most likely
attributed to the relatively small sample size.Our results should, there-
fore, be confirmed in a larger study. Third, we also included patients
who were diagnosed on the basis of a multidisciplinary team deci-
sion. However, the results do not differ between the PCR-positive and
the combined PCR/multidisciplinary team–positive groups. Fourth, we
tried to minimize incorporation bias by blinding the radiologists and
scanning physicians to each other’s results. However, they were aware
of the patients’ clinical parameters. Although this may have caused an
upward adjustment of the LUS and CTSS in patients who were sicker
and vice versa in patients who were less sick, we would have expected
this to apply to CT and the LUS to the same degree. Moreover, blinding
them entirely from the patient’s clinical information was not desirable
as this does not reflect daily practice.
4 DISCUSSION
To our knowledge, this is the first multicenter study to prospectively
compare the correlation between the LUS and CTSS in COVID-19 and
assess the ability of the LUS to discriminate COVID-19 pneumonia dis-
ease severity and its association with prognosis.
Our results showthatCOVID-19pulmonary involvementquantified
by the semiquantitative LUS is strongly correlated with the pulmonary
involvement assessed by CT. An increasing LUS is also positively asso-
ciated with disease severity. This is consistent with other findings on
viral pneumonias and acute respiratory distress syndrome15,30 as well
as recent retrospective data in COVID-19.16,24,43 TheWHO and Fleis-
chner Society agree that imaging studies should be considered in the
triage andmanagement of patients, especially in resource-constrained
environments (eg, no immediate PCR results) and in patients with at
least moderate disease.26,44 Although CT is considered the gold stan-
dard to assess the degree of pulmonary involvement, our findings indi-
cate that lung ultrasound could be a viable alternative to CT in the
initial assessment of lung involvement in COVID-19. Initially, it was
believed that lung ultrasoundwould be less reliable thanCTbecause of
its perceived inability to detect central lesions.44 However, the periph-
eral distribution of COVID-19 makes lung ultrasound ideal for the
detection of these abnormalities.21,45,46 In fact, lung ultrasound also
serves as a reliable test in viral pneumonias that produce more central
abnormalities, such as influenza.47–49 Incorporating lung ultrasound
into routine COVID-19 diagnostics offers the potential of reducing
stress on conventional radiological resources, decreasing the need of
transporting patients who are ill and unstable to CT and lowering the
amount of healthcare personnel exposed to patients who are poten-
tially contagious.24,50
Furthermore, the LUS is able to discriminate well between patients
who require admission and those who do not. Interestingly, the LUS
could do so just as well as the CTSS. Furthermore, the gray zone anal-
ysis indicates that the LUS changes the posttest probability of admis-
sionmoderately (∼30%) inmore than two-thirds of patients and largely
(∼45%) in almost half of the patients, which is also comparable with
the CTSS.2 Previous studies found that chest imaging features can pre-
date clinical symptoms or deterioration.4,5 It has even been suggested
that imaging findings might have additional value to clinical prognos-
tic factors in selecting patients with COVID-19 with high risks of poor
outcomes irrespective of clinical presentation or disease course.51,52
Our findings show that baseline lung ultrasound is indeed a predictor
of poor outcome at 30 days and prolonged admission. These results
are in line with the literature on CT with COVID-19 that shows that
pulmonary involvement on CTmight be associated independently with
outcome.2,4,5,53 Sensitivity analysis shows no significant differences
between the imputed and complete case data. Two recent retrospec-
tive single-center studies from Israel and the United Kingdom show
a similar association between lung ultrasound and poor outcomes in
COVID-19.17,24 Our results add to the accumulating evidence that a
semiquantitative LUS, as a proxy for lung involvement, is predictive of
a poor outcome in a range of other pathologies, such as acute respi-
ratory distress syndrome and heart failure.15,54 It is still unclear, how-
ever, how lung ultrasound should be incorporated with other biomark-
ers and clinical information. Patientswith a higher LUS tend to bemore
ill, with increases inC-reactive protein, neutrophils, lactate dehydroge-
nase, and modified early warning score (MEWS) (Table 1). Combining
lung ultrasound (and other POCUS modalities) with additional known
prognostic factors for poor outcomesmay enhance existing risk scores,
as has been the case with CT findings.51,52
Time at the frontlines is of the essence; clinicians require tools that
enable them to make quick and accurate diagnostic and management
decisions. Reliability and speed are even more critical as waves of
patientswithCOVID-19keepoverwhelmingEDsandcloggingupacute
(and regular) care pathways. Integrating POCUS into clinical decision
making has shown to speed up diagnosis and improve patient triage
and time to treatment at the ED significantly.12,55 Lung ultrasound in
COVID-19 may be of particular additional value to the physical exami-
nation and sound clinical judgment in patients who do not present with
overt symptoms (eg, silent hypoxia or desaturation only with exercise)
but might still benefit from a higher level of monitoring based on a
high LUS. One could also speculate that serial point-of-care lung ultra-
sound might be used to monitor pulmonary involvement, track the dis-
ease course, guidemanagement, and determine response to treatment
without any radiation exposure. The LUSmight also be awelcome addi-
tion to laboratory markers given the speed with which the results of
POCUS are available. Lung ultrasound results can be obtained within
5–10minutes,which ismuch faster than traditional laboratory or imag-
ing results. Fortunately, POCUS is simple to learn for (para)medical
personnel.56,57 Furthermore, as an affordable and easy-to-use tool,
POCUS could reduce obstacles to proper care, which is of particular
importance given the ethnoracial, cultural, and socioeconomic dispar-
ities COVID-19 has laid bare worldwide.58,59 Moreover, POCUS can
be used in different care settings (eg, ED, family practice, care homes,
rural medicine), further lowering barriers to adequate care during this
pandemic.60,61 Future research should focus on the value of serial LUS
inmonitoring and response to treatment, implementation of POCUS in
different settings (eg, nursing homes, outpatient facilities, community
health centers, and general practitioner triage), and the development
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and validation of predictive models intergrating the LUS with other
prognostic factors.
In summary, we demonstrate that the LUS correlates well with
the CTSS. Moreover, COVID-19 pulmonary involvement measured by
lung ultrasound is significantly associated with poor outcome, disease
severity, and admission duration. Lung ultrasound may, therefore, help
the triage, risk stratification, andmanagement of patientswithCOVID-
19 at the ED.
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